Alexion Reports First Quarter 2017 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Alexion Pharma (ALXN) Tops Q1 EPS by 15c; Raises Outlook
April 27, 2017 6:32 AM EDTAlexion Pharma (NASDAQ: ALXN) reported Q1 EPS of $1.38, $0.15 better than the analyst estimate of $1.23. Revenue for the quarter came in at $870 million versus the consensus estimate of $827.2 million.
1Q17 Total Revenues of $870 Million, a 24% Increase and 26% Volume Increase Year-Over-YearRevenue Growth Benefited from Continued Strong Volume Growth of Soliris® In Core MarketsStrensiq® Revenue Driven by Steady Addition of New Patients Starting... More